Areas of uncertainty on the diagnosis, treatment, and follow-up of hypophosphatemia in adults: an Italian Delphi consensus.
Journal
Journal of endocrinological investigation
ISSN: 1720-8386
Titre abrégé: J Endocrinol Invest
Pays: Italy
ID NLM: 7806594
Informations de publication
Date de publication:
08 Oct 2024
08 Oct 2024
Historique:
received:
16
04
2024
accepted:
22
08
2024
medline:
8
10
2024
pubmed:
8
10
2024
entrez:
8
10
2024
Statut:
aheadofprint
Résumé
The study aimed to present the results of a Delphi consensus involving Italian experts focusing on the management of hypophosphatemia in adults. A multidisciplinary advisory board of nine physicians, experts in hypophosphatemia management, was established. Next, a literature search was performed to identify international guidelines, consensus, and clinical pathways, which were later presented to the advisory board. Collaboratively, the advisory board and authoring team selected key statements for the consensus process and focused on areas of uncertainty related to the management of hypophosphatemia. The advisory board also indicated the experts to be invited to participate in the consensus process. The Delphi method was employed to reach a consensus. The literature search yielded one guideline, five consensus documents, and one clinical pathway. While our search strategy aimed to identify documents on the management of all types of hypophosphatemia, most of the guidelines and consensus documents retrieved focused on X-linked hypophosphatemia. The consensus process focused on 11 key issues, achieving strong convergence (over 70% consensus) in the first Delphi round for 8 out of the 11 statements. Three statements proceeded to the second round, with strong agreement reached for two. Notably, consensus was not reached for the statement concerning the measurement of fibroblast growth factor 23 for diagnostic purposes. The study revealed that the community of clinical experts is well-informed and in agreement regarding hypophosphatemia management. It emphasized the importance of developing clear national guidance documents to support clinicians and multidisciplinary teams in patient management. These documents are crucial not only for healthcare professionals but also for those responsible for defining pathways and services, facilitating a more accurate management of hypophosphatemic patients.
Identifiants
pubmed: 39377903
doi: 10.1007/s40618-024-02458-4
pii: 10.1007/s40618-024-02458-4
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Kyowa Kirin
ID : Kyowa Kirin
Investigateurs
Maria Rosaria Ambrosio
(MR)
Elisa Cairoli
(E)
Valentina Camozzi
(V)
Salvatore Cannavò
(S)
Cristina Eller-Vainicher
(C)
Sandro Gianninir
(S)
Laura Gianotti
(L)
Andrea Giusti
(A)
Daniela Merlotti
(D)
Silvia Migliaccio
(S)
Salvatore Minisola
(S)
Vincenzo Montinaro
(V)
Andrea Palermo
(A)
Daniela Pasquali
(D)
Giovanni Passeri
(G)
Massimo Procopio
(M)
Antonio Stefano Salcuni
(AS)
Informations de copyright
© 2024. The Author(s).
Références
Giannini S, Bianchi ML, Rendina D, Massoletti P, Lazzerini D, Brandi ML (2021) Burden of disease and clinical targets in adult patients with X-linked hypophosphatemia. A comprehensive review. Osteoporos Int 32(10):1937–1949
doi: 10.1007/s00198-021-05997-1
pubmed: 34009447
pmcid: 8510985
Raimann A, Mindler GT, Kocijan R, Bekes K, Zwerina J, Haeusler G et al (2020) Multidisciplinary patient care in X-linked hypophosphatemic rickets: one challenge, many perspectives. Wien Med Wochenschr 170(5–6):116–123
doi: 10.1007/s10354-019-00732-2
pubmed: 31993875
pmcid: 7098922
Bosman A, Palermo A, Vanderhulst J, De Beur SMJ, Fukumoto S, Minisola S et al (2022) Tumor-Induced Osteomalacia: a systematic clinical review of 895 cases. Calcif Tissue Int 111(4):367–379
doi: 10.1007/s00223-022-01005-8
pubmed: 35857061
pmcid: 9474374
Abate V, Vergatti A, De Filippo G, Damiano V, Menale C, D’Elia L et al (2024) Clinical characteristics of malignant phosphaturic mesenchymal tumor causing Tumor-Induced Osteomalacia. J Clin Endocrinol Metab 109(3):e1006–e11
doi: 10.1210/clinem/dgad690
pubmed: 38006315
Ni X, Guan W, Jiang Y, Li X, Chi Y, Pang Q et al (2023) High prevalence of vertebral deformity in tumor-induced osteomalacia associated with impaired bone microstructure. J Endocrinol Invest 46(3):487–500
doi: 10.1007/s40618-022-01918-z
pubmed: 36097315
Haffner D, Emma F, Eastwood DM, Duplan MB, Bacchetta J, Schnabel D et al (2019) Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia. Nat Rev Nephrol 15(7):435–455
doi: 10.1038/s41581-019-0152-5
pubmed: 31068690
pmcid: 7136170
Laurent MR, De Schepper J, Trouet D, Godefroid N, Boros E, Heinrichs C et al (2021) Consensus recommendations for the diagnosis and management of X-Linked hypophosphatemia in Belgium. Front Endocrinol (Lausanne) 12:641543
doi: 10.3389/fendo.2021.641543
pubmed: 33815294
Trombetti A, Al-Daghri N, Brandi ML, Cannata-Andia JB, Cavalier E, Chandran M et al (2022) Interdisciplinary management of FGF23-related phosphate wasting syndromes: a Consensus Statement on the evaluation, diagnosis and care of patients with X-linked hypophosphataemia. Nat Reviews Endocrinol 18(6):366–384
doi: 10.1038/s41574-022-00662-x
Jan de Beur SM, Minisola S, Xia WB, Abrahamsen B, Body JJ, Brandi ML et al (2023) Global guidance for the recognition, diagnosis, and management of tumor-induced osteomalacia. J Intern Med 293(3):309–328
doi: 10.1111/joim.13593
pubmed: 36511653
Nasa P, Jain R, Juneja D (2021) Delphi methodology in healthcare research: how to decide its appropriateness. World J Methodol 11(4):116–129
doi: 10.5662/wjm.v11.i4.116
pubmed: 34322364
pmcid: 8299905
Pivonello R, Scaroni C, Polistena B, Migliore A, Giustina A (2023) Unmet needs on the current medical management of Cushing’s syndrome: results from a Delphi panel of Italian endocrinologists. J Endocrinol Invest 46(9):1923–1934
doi: 10.1007/s40618-023-02058-8
pubmed: 37076758
pmcid: 10115381
Dahir KM, Rush ET, Diaz-Mendoza S, Kishnani PS (2024) A Delphi panel to build consensus on assessing disease severity and disease progression in adult patients with hypophosphatasia in the United States. J Endocrinol Invest 47(6):1487–1497
doi: 10.1007/s40618-023-02256-4
pubmed: 38236379
pmcid: 11142979
Carpenter TO, Imel EA, Holm IA, Jan de Beur SM, Insogna KL (2011) A clinician’s guide to X-linked hypophosphatemia. J Bone Min Res 26(7):1381–1388
doi: 10.1002/jbmr.340
Dahir K, Dhaliwal R, Simmons J, Imel EA, Gottesman GS, Mahan JD et al (2022) Health Care Transition from Pediatric- to adult-focused care in X-linked hypophosphatemia: Expert Consensus. J Clin Endocrinol Metabolism 107(3):599–613
doi: 10.1210/clinem/dgab796
Garcia Martin A, Varsavsky M, Cortes Berdonces M, Avila Rubio V, Alhambra Exposito MR, Novo Rodriguez C et al (2020) Phosphate disorders and clinical management of hypophosphatemia and hyperphosphatemia. Endocrinol Diabetes Nutr (Engl Ed) 67(3):205–215
pubmed: 31501071
Baroncelli G et al (2020) PDTAA18 RACHITISMO IPOFOSFATEMICO: DIAGNOSI, TERAPIA E FOLLOW-UP. https://www.ao-pisa.toscana.it/index.php?option=com_attachments&task=download&id=8097 (last access: 29/05/2023)
Arcidiacono GP, Camozzi V, Zaninotto M, Tripepi G, Fusaro M, Torres MO et al (2024) Tubular phosphate transport: a comparison between different methods of urine sample collection in FGF23-dependent hypophosphatemic syndromes. Clin Chem Lab Med 62(6):1126–1132
doi: 10.1515/cclm-2023-1292
pubmed: 38295343
Rendina D, Abate V, Cacace G, Elia L, De Filippo G, Del Vecchio S et al (2022) Tumor induced osteomalacia: a systematic review and individual patient’s data analysis. J Clin Endocrinol Metab
Padidela R, Cheung MS, Saraff V, Dharmaraj P (2020) Clinical guidelines for burosumab in the treatment of XLH in children and adolescents: British paediatric and adolescent bone group recommendations. Endocr Connect 9(10):1051–1056
doi: 10.1530/EC-20-0291
pubmed: 33112809
pmcid: 7707830
Gazzetta Ufficiale Serie Generale n 71 del 24-03-2023, Determina n. 210/2023 ( www.gazzettaufficiale.it/eli/id/2023/03/24/23A01737/sg )
Crysvita EPAR - Product Information, https://www.ema.europa.eu/en/documents/product-information/crysvita-epar-product-information_en.pdf (accessed 17/03/2024)
Bergwitz C, Miyamoto KI (2019) Hereditary hypophosphatemic rickets with hypercalciuria: pathophysiology, clinical presentation, diagnosis and therapy. Pflugers Arch 471(1):149–163
doi: 10.1007/s00424-018-2184-2
pubmed: 30109410